出版：MarketsandMarkets（マーケッツアンドマーケッツ） 出版年月：2023年10月
HLA Typing for Transplant Market – Global Forecasts to 2028
移植用 HLA タイピング市場 : テクノロジー [PCR (SSO、SSP、リアルタイム)、シーケンス (NGS、サンガー)]、製品 (機器、キット、ソフトウェア)、用途 (抗体スクリーニング)、タイプ (臓器移植、組織)、エンドユーザー、地域別 – 2028年までの世界予測
HLA Typing for Transplant Market by Technology (PCR (SSO, SSP, Real Time), Sequencing (NGS, Sanger)), Product (Instrument, Kits, Software), Application (Antibody Screening), Type (Organ Transplant, Tissue), End User, and Region – Global Forecast to 2028
| ページ数 | 206 |
| 図表数 | 201 |
| 種別 | 英文調査報告書 |
| 価格 |
Report Overview
The global HLA typing for the transplants market is expected to reach USD 1.1 billion by 2028 from USD 0.8 billion in 2023, at a CAGR of 6.3%. Rising technological advancements in the field of HLA typing, increasing demand for transplantation, rising initiatives by the government to boost the organ donation, and increasing research activities in field of HLA typing to support the market growth.
“The independent reference laboratories segment accounted for the largest share of the HLA typing for transplants market, by end-user, in 2022.”
Based on end user, the HLA typing for transplants market is segmented into hospitals & transplant centers, independent reference laboratories, and research laboratories & academic institutes. In 2022, independent reference laboratories accounted for the largest share of the HLA typing for transplants . This is attributed the growing preference of diagnostic laboratories to outsource the HLA typing services by biotechnology companies, presence of high resolution molecular technology , and increasing collaboration among reference laboratories and transplant centers
“The molecular assay technologies segment accounted for the largest share of the HLA typing for transplants market, by technology, in 2022.”
The HLA typing for transplants market, by technology, is segmented into non-molecular and molecular assay technologies. In 2022, the molecular assay technologies segment accounted for the largest share of the HLA typing for transplants market. This is attributed to the strong adoption of molecular technology for HLA typing among end user setting and strong focus of manufacturers towards the development of high resolution assays for the molecular technologies
“North America accounted for the largest share of the HLA typing for transplants market in 2022.”
North America accounted for the largest share of the HLA typing for transplants market in 2022, followed by Europe. This can primarily be availability of advanced diagnostic technology, increased presence of manufacturers, and well established healthcare infrastructure.
Additionally, presence of prominent biotechnology companies engaged in the research of new HLA alleles, increasing transplantation rates, and favorable reimbursement policy to support the growth of market in the region
Breakdown of supply-side primary interviews:
• By Company Type: Tier 1 (48%), Tier 2 (36%), and Tier 3 (16%)
• By Designation: C-level (10%), Director-level (14%), and Others (76%)
• By Region: North America (40%), Europe (32%), APAC (20%), Latin America (5%) and MEA (3%)
Some of the prominent players in the HLA typing for transplants market are Thermo Fisher Scientific, Inc. (US), QIAGEN (Germany), Illumina (US), CareDx, Inc. (US), Immucor, Inc. (US), Bio-Rad Laboratories, Inc. (US), F. Hoffman-La Roche Ltd. (Switzerland), Hologic, Inc. (US), Luminex Corporation(US)
Research Coverage
This report studies the HLA typing for transplants market based on product& service, technology, transplant type, application, end-user, and region. It studies major factors (such as drivers and restraints) affecting market growth. The report also analyzes opportunities and challenges in the market for stakeholders and provides details of the competitive landscape for market leaders. It the the with respect to their individual growth trends, prospects, and contributions to the total market. The report forecasts the revenue of market segments with respect to five major regions and their respective major countries.
Reasons to Buy the Report
The report will enable established firms as well as entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them to garner a larger market share. Firms purchasing the report could use one or a combination of the below-mentioned strategies to strengthen their market presence.
This report provides insights on the following pointers:
• Analysis of key drivers ( increasing transplantation rates, growing technological advancements, increasing government initiatives to boost HLA typing services in transplantation) restraints (high cost of molecular test use in HLA typing procedures), opportunities (technological shift from non-molecular serological assay to molecular assay, high growth offered by emerging markets), and challenges (Significant gap between number of organ donors and transplant recipients) influencing the growth of HLA typing for transplant market
n Market Penetration: Comprehensive information on the product portfolios offered by the top players in the HLA typing for transplant market
n Product Development/Innovation: Detailed insights on the upcoming trends, R&D activities, and product launches in the HLA typing for transplant market
n Market Development: Comprehensive information on lucrative emerging regions
n Market Diversification: Exhaustive information about new products, growing geographies, and recent developments in the HLA typing for transplant market
n Competitive Assessment: In-depth assessment of market segments, growth strategies, revenue analysis, and products of the leading market players.
Table of Contents
1 INTRODUCTION 29
1.1 STUDY OBJECTIVES 29
1.2 MARKET DEFINITION 29
1.2.1 INCLUSIONS AND EXCLUSIONS 29
1.3 STUDY SCOPE 30
1.3.1 MARKETS COVERED 30
1.3.2 REGIONS COVERED 30
1.3.3 YEARS CONSIDERED 31
1.3.4 CURRENCY CONSIDERED 31
1.4 KEY STAKEHOLDERS 31
1.5 SUMMARY OF CHANGES 32
1.6 RECESSION IMPACT: HLA TYPING FOR TRANSPLANTS MARKET 32
2 RESEARCH METHODOLOGY 33
2.1 RESEARCH DATA 33
FIGURE 1 RESEARCH DESIGN 33
2.1.1 SECONDARY DATA 34
2.1.2 PRIMARY RESEARCH 35
2.1.2.1 Key data from primary sources 35
FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS 36
FIGURE 3 GLOBAL HLA TYPING FOR TRANSPLANTS MARKET: BREAKDOWN OF PRIMARIES 36
2.2 MARKET SIZE ESTIMATION METHODOLOGY 36
FIGURE 4 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING 37
2.2.1 REVENUE MAPPING-BASED MARKET ESTIMATION 38
2.2.2 PROCEDURE-BASED MARKET ESTIMATION 38
FIGURE 5 MARKET SIZE ESTIMATION: HLA TYPING FOR TRANSPLANTS MARKET 39
2.2.3 PRIMARY RESEARCH VALIDATION 39
2.3 DATA TRIANGULATION 40
FIGURE 6 DATA TRIANGULATION METHODOLOGY 40
2.4 RESEARCH ASSUMPTIONS AND LIMITATIONS 41
2.4.1 RESEARCH ASSUMPTIONS 41
2.4.2 RESEARCH LIMITATIONS 41
2.5 RECESSION IMPACT ANALYSIS 42
TABLE 1 GLOBAL INFLATION RATE PROJECTIONS, 2021–2027 (% GROWTH) 42
3 EXECUTIVE SUMMARY 43
FIGURE 7 HLA TYPING FOR TRANSPLANTS MARKET SHARE, BY PRODUCT & SERVICE, 2023 VS. 2028 43
FIGURE 8 HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2023 VS. 2028 (USD MILLION) 44
FIGURE 9 HLA TYPING FOR TRANSPLANTS MARKET, BY END USER, 2023 VS. 2028 (USD MILLION) 44
FIGURE 10 HLA TYPING FOR TRANSPLANTS MARKET: GEOGRAPHIC SNAPSHOT (2022) 45
4 PREMIUM INSIGHTS 46
4.1 HLA TYPING FOR TRANSPLANTS MARKET OVERVIEW 46
FIGURE 11 INCREASING NUMBER OF TRANSPLANT PROCEDURES TO DRIVE MARKET 46
4.2 NORTH AMERICA: HLA TYPING FOR TRANSPLANTS MARKET SHARE, BY PRODUCT & SERVICE & COUNTRY (2022) 47
FIGURE 12 REAGENTS & CONSUMABLES ACCOUNTED FOR LARGEST MARKET SHARE IN 2022 47
4.3 HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2023 VS. 2028 (USD MILLION) 47
FIGURE 13 MOLECULAR ASSAY TECHNOLOGIES SEGMENT TO RETAIN DOMINANCE TILL 2028 47
4.4 MOLECULAR ASSAY TECHNOLOGIES MARKET, 2023 VS. 2028 48
FIGURE 14 NGS TO REGISTER HIGHEST GROWTH 48
4.5 HLA TYPING FOR TRANSPLANTS MARKET SHARE, BY END USER, 2023 VS. 2028 (USD MILLION) 48
FIGURE 15 INDEPENDENT REFERENCE LABORATORY SEGMENT TO DOMINATE MARKET TILL 2028 48
4.6 HLA TYPING FOR TRANSPLANTS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 49
FIGURE 16 CHINA TO REGISTER HIGHEST GROWTH FROM 2023 TO 2028 49
5 MARKET OVERVIEW 50
5.1 INTRODUCTION 50
5.2 MARKET DYNAMICS 50
FIGURE 17 HLA TYPING FOR TRANSPLANTS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 50
5.2.1 DRIVERS 51
5.2.1.1 Increasing number of transplant procedures globally 51
5.2.1.2 Technological advancements in HLA typing 51
5.2.1.3 Government initiatives to boost HLA typing services in transplantation 52
5.2.2 RESTRAINTS 52
5.2.2.1 High cost of molecular tests used for HLA typing 52
TABLE 2 COST OF ASSAYS FOR MAJOR NGS/PCR-BASED GENOMIC TESTS IN EUROPE (AS OF 2022) 53
5.2.2.2 Limited reimbursements for target procedures in emerging countries 53
5.2.3 OPPORTUNITIES 54
5.2.3.1 Rising adoption of cross-matching and chimerism testing pre/post-transplantation 54
5.2.3.2 Technological shift from non-molecular serological assays to gene-based HLA profiling 54
5.2.4 CHALLENGES 54
5.2.4.1 Significant gap in organ demand and supply 54
5.3 PRICING ANALYSIS 55
5.3.1 INDICATIVE PRICING MODEL ANALYSIS OF MARKET PLAYERS 55
TABLE 3 INDICATIVE PRICING FOR HLA TYPING INSTRUMENTS, REAGENTS, AND KITS FOR TRANSPLANTATION 55
5.3.2 AVERAGE SELLING PRICE OF HLA TYPING INSTRUMENTS, BY KEY PLAYER 56
TABLE 4 AVERAGE SELLING PRICE OF HLA TYPING FOR TRANSPLANT PRODUCTS 56
5.4 PATENT ANALYSIS 57
FIGURE 18 PATENT ANALYSIS OF NEXT-GENERATION SEQUENCING TECHNOLOGIES 57
5.5 VALUE CHAIN ANALYSIS 58
FIGURE 19 VALUE CHAIN ANALYSIS OF HLA TYPING FOR TRANSPLANTS MARKET: MAJOR VALUE-ADDED DURING MANUFACTURING AND ASSEMBLY PHASES 58
5.6 SUPPLY CHAIN ANALYSIS 59
FIGURE 20 HLA TYPING FOR TRANSPLANTS MARKET: SUPPLY CHAIN ANALYSIS 60
5.7 ECOSYSTEM MAPPING 60
FIGURE 21 HLA TYPING FOR TRANSPLANTS MARKET: ECOSYSTEM MAP 60
5.8 PORTER’S FIVE FORCES ANALYSIS 61
TABLE 5 HLA TYPING FOR TRANSPLANTS MARKET: PORTER’S FIVE FORCES ANALYSIS 61
5.8.1 THREAT OF NEW ENTRANTS 61
5.8.2 THREAT OF SUBSTITUTES 61
5.8.3 BARGAINING POWER OF BUYERS 61
5.8.4 BARGAINING POWER OF SUPPLIERS 61
5.8.5 DEGREE OF COMPETITION 62
5.9 REIMBURSEMENT SCENARIO 62
TABLE 6 CPT CODES FOR MOLECULAR DIAGNOSTICS: HLA TESTING FOR TRANSPLANT HISTOCOMPATIBILITY 62
5.10 REGULATORY LANDSCAPE 63
TABLE 7 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 63
TABLE 8 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 63
TABLE 9 LATIN AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 63
TABLE 10 REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 64
5.10.1 NORTH AMERICA 64
5.10.1.1 US 64
5.10.1.2 Canada 64
5.10.2 EUROPE 64
5.10.3 ASIA PACIFIC 65
5.10.3.1 China 65
5.10.3.2 Japan 65
TABLE 11 JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 65
5.10.3.3 India 65
5.10.4 LATIN AMERICA 66
5.10.4.1 Brazil 66
5.10.5 MIDDLE EAST 66
5.11 KEY CONFERENCES & EVENTS, 2023–2025 67
TABLE 12 HLA TYPING FOR TRANSPLANTS MARKET: DETAILED LIST OF CONFERENCES & EVENTS, 2023–2025 67
5.12 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 68
FIGURE 22 REVENUE SHIFT IN HLA TYPING FOR TRANSPLANTS MARKET 68
5.13 TRADE ANALYSIS 68
5.13.1 TRADE ANALYSIS FOR DIAGNOSTIC AND LABORATORY REAGENTS 68
TABLE 13 IMPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS, BY COUNTRY, 2018–2022 (USD MILLION) 68
TABLE 14 EXPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS, BY COUNTRY, 2018–2022 (USD MILLION) 69
5.14 KEY STAKEHOLDERS & BUYING CRITERIA 69
5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS 69
FIGURE 23 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF MARKET PRODUCTS 69
TABLE 15 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF MARKET PRODUCTS (%) 69
5.14.2 BUYING CRITERIA 70
FIGURE 24 KEY BUYING CRITERIA FOR MARKET PRODUCTS 70
TABLE 16 KEY BUYING CRITERIA FOR HLA TYPING FOR MARKET PRODUCTS 70
6 HLA TYPING FOR TRANSPLANTS MARKET, BY PRODUCT & SERVICE 71
6.1 INTRODUCTION 72
TABLE 17 HLA TYPING FOR TRANSPLANTS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 72
6.2 REAGENTS & CONSUMABLES 72
6.2.1 REAGENTS & CONSUMABLES TO HOLD LARGEST MARKET SHARE 72
TABLE 18 HLA TYPING REAGENTS & CONSUMABLES MARKET, BY REGION, 2021–2028 (USD MILLION) 73
6.3 INSTRUMENTS 73
6.3.1 ADVANCEMENTS IN HLA-BASED GENOME PROFILING TO SUPPORT SEGMENT GROWTH 73
TABLE 19 HLA TYPING INSTRUMENTS MARKET, BY REGION, 2021–2028 (USD MILLION) 74
6.4 SOFTWARE & SERVICES 74
6.4.1 RISING DEMAND FOR INNOVATIVE SOFTWARE TO DRIVE MARKET 74
TABLE 20 HLA TYPING SOFTWARE & SERVICES MARKET, BY REGION, 2021–2028 (USD MILLION) 75
7 HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY 76
7.1 INTRODUCTION 77
TABLE 21 HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 77
7.2 MOLECULAR ASSAY TECHNOLOGIES 77
TABLE 22 MOLECULAR ASSAY TECHNOLOGIES MARKET, BY TYPE, 2021–2028 (USD MILLION) 77
TABLE 23 MOLECULAR ASSAY TECHNOLOGIES MARKET, BY REGION, 2021–2028 (USD MILLION) 78
7.2.1 PCR-BASED MOLECULAR ASSAYS 78
TABLE 24 PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2021–2028 (USD MILLION) 79
TABLE 25 PCR-BASED MOLECULAR ASSAYS MARKET, BY REGION, 2021–2028 (USD MILLION) 79
7.2.1.1 Sequence-specific primer-PCR 79
7.2.1.1.1 Growing public-private investments in research to support market growth 79
TABLE 26 SEQUENCE-SPECIFIC PRIMER-PCR MARKET, BY REGION, 2021–2028 (USD MILLION) 80
7.2.1.2 Sequence-specific oligonucleotide-PCR 80
7.2.1.2.1 Growing awareness of benefits among medical professionals to drive demand 80
TABLE 27 SEQUENCE-SPECIFIC OLIGONUCLEOTIDE-PCR MARKET, BY REGION, 2021–2028 (USD MILLION) 81
7.2.1.3 Real-time PCR 81
7.2.1.3.1 High cost of real-time PCR and procedural complexity to hamper market growth 81
TABLE 28 REAL-TIME PCR MARKET, BY REGION, 2021–2028 (USD MILLION) 82
7.2.1.4 Other PCR-based molecular assays 82
TABLE 29 OTHER PCR-BASED MOLECULAR ASSAYS MARKET, BY REGION, 2021–2028 (USD MILLION) 82
7.2.2 SEQUENCING-BASED MOLECULAR ASSAYS 83
TABLE 30 SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2021–2028 (USD MILLION) 83
TABLE 31 SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY REGION, 2021–2028 (USD MILLION) 83
7.2.2.1 Sanger sequencing 84
7.2.2.1.1 Growing demand for high-throughput DNA sequencers to drive market 84
TABLE 32 SANGER SEQUENCING MARKET, BY REGION, 2021–2028 (USD MILLION) 84
7.2.2.2 NGS 84
7.2.2.2.1 High scalability, low turnaround time, and other advantages to boost adoption 84
TABLE 33 NGS MARKET, BY REGION, 2021–2028 (USD MILLION) 85
7.2.2.3 Other sequencing-based molecular assays 85
TABLE 34 OTHER SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY REGION, 2021–2028 (USD MILLION) 85
7.3 NON-MOLECULAR ASSAY TECHNOLOGIES 86
7.3.1 REPLACEMENT OF NON-MOLECULAR TECHNIQUES WITH DNA-BASED HLA TYPING TO HAMPER MARKET GROWTH 86
TABLE 35 NON-MOLECULAR ASSAY TECHNOLOGIES MARKET, BY REGION, 2021–2028 (USD MILLION) 86
8 HLA TYPING FOR TRANSPLANTS MARKET, BY APPLICATION 87
8.1 INTRODUCTION 88
TABLE 36 HLA TYPING FOR TRANSPLANTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 88
8.2 DIAGNOSTIC APPLICATIONS 88
TABLE 37 HLA TYPING FOR TRANSPLANTS MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION) 88
TABLE 38 HLA TYPING FOR TRANSPLANTS MARKET FOR DIAGNOSTIC APPLICATIONS, BY REGION, 2021–2028 (USD MILLION) 89
8.2.1 ANTIBODY SCREENING 89
8.2.1.1 Rising number of recipients for transplant procedures to drive market growth 89
TABLE 39 ANTIBODY SCREENING MARKET, BY REGION, 2021–2028 (USD MILLION) 90
8.2.2 CHIMERISM MONITORING 90
8.2.2.1 Rising trend of personalized transplant medicine for effective risk management to support market growth 90
TABLE 40 CHIMERISM MONITORING MARKET, BY REGION, 2021–2028 (USD MILLION) 90
8.2.3 OTHER APPLICATIONS 91
TABLE 41 OTHER DIAGNOSTIC APPLICATIONS MARKET, BY REGION, 2021–2028 (USD MILLION) 91
8.3 RESEARCH APPLICATIONS 91
8.3.1 RISING INVESTMENTS AND SUPPORT FOR RESEARCH TO DRIVE MARKET 91
TABLE 42 HLA TYPING FOR TRANSPLANTS MARKET FOR RESEARCH APPLICATIONS, BY REGION, 2021–2028 (USD MILLION) 92
9 HLA TYPING FOR TRANSPLANTS MARKET, BY TRANSPLANT TYPE 93
9.1 INTRODUCTION 94
TABLE 43 HLA TYPING FOR TRANSPLANTS MARKET, BY TRANSPLANT TYPE, 2021–2028 (USD MILLION) 94
9.2 SOLID ORGAN TRANSPLANTS 94
9.2.1 SOLID ORGAN TRANSPLANTS TO HOLD LARGEST MARKET SHARE 94
TABLE 44 HLA TYPING FOR SOLID ORGAN TRANSPLANTS MARKET, BY REGION, 2021–2028 (USD MILLION) 95
9.3 SOFT TISSUE TRANSPLANTS 95
9.3.1 INCREASING BLOOD CANCER PREVALENCE TO BOOST DEMAND 95
TABLE 45 HLA TYPING FOR SOFT TISSUE TRANSPLANTS MARKET, BY REGION, 2021–2028 (USD MILLION) 96
10 HLA TYPING FOR TRANSPLANTS MARKET, BY END USER 97
10.1 INTRODUCTION 98
TABLE 46 HLA TYPING FOR TRANSPLANTS MARKET, BY END USER, 2021–2028 (USD MILLION) 98
10.2 INDEPENDENT REFERENCE LABORATORIES 98
10.2.1 INDEPENDENT LABS TO HOLD LARGEST MARKET SHARE 98
TABLE 47 HLA TYPING FOR TRANSPLANTS MARKET FOR INDEPENDENT REFERENCE LABORATORIES, 2021–2028 (USD MILLION) 99
10.3 HOSPITALS & TRANSPLANT CENTERS 99
10.3.1 RISING TRANSPLANT VOLUMES TO DRIVE DEMAND FOR HLA TYPING 99
TABLE 48 HLA TYPING FOR TRANSPLANTS MARKET FOR HOSPITALS & TRANSPLANT CENTERS, 2021–2028 (USD MILLION) 100
10.4 RESEARCH LABORATORIES & ACADEMIC INSTITUTES 100
10.4.1 RISING RESEARCH ACTIVITY TO DRIVE MARKET 100
TABLE 49 HLA TYPING FOR TRANSPLANTS MARKET FOR RESEARCH LABORATORIES & ACADEMIC INSTITUTES, 2021–2028 (USD MILLION) 101
11 HLA TYPING FOR TRANSPLANTS MARKET, BY REGION 102
11.1 INTRODUCTION 103
TABLE 50 HLA TYPING FOR TRANSPLANTS MARKET, BY REGION, 2021–2028 (USD MILLION) 103
11.2 NORTH AMERICA 103
11.2.1 NORTH AMERICA: RECESSION IMPACT 103
FIGURE 25 NORTH AMERICA: HLA TYPING FOR TRANSPLANTS MARKET SNAPSHOT 104
TABLE 51 NORTH AMERICA: HLA TYPING FOR TRANSPLANTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 104
TABLE 52 NORTH AMERICA: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 105
TABLE 53 NORTH AMERICA: HLA TYPING FOR TRANSPLANTS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 105
TABLE 54 NORTH AMERICA: HLA TYPING FOR TRANSPLANTS MARKET, BY END USER, 2021–2028 (USD MILLION) 105
11.2.2 US 106
11.2.2.1 US to hold largest market share 106
FIGURE 26 US: SOLID ORGAN TRANSPLANTATIONS PERFORMED, 2019–2021 106
TABLE 55 US: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 106
TABLE 56 US: MOLECULAR ASSAY TECHNOLOGIES MARKET, BY TYPE, 2021–2028 (USD MILLION) 107
TABLE 57 US: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2021–2028 (USD MILLION) 107
TABLE 58 US: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2021–2028 (USD MILLION) 107
11.2.3 CANADA 108
11.2.3.1 Rising availability of transplant diagnostic products to support market growth 108
TABLE 59 CANADA: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 108
TABLE 60 CANADA: MOLECULAR ASSAY TECHNOLOGIES MARKET, BY TYPE, 2021–2028 (USD MILLION) 108
TABLE 61 CANADA: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2021–2028 (USD MILLION) 109
TABLE 62 CANADA: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2021–2028 (USD MILLION) 109
11.3 EUROPE 109
11.3.1 EUROPE: RECESSION IMPACT 110
TABLE 63 EUROPE: HLA TYPING FOR TRANSPLANTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 110
TABLE 64 EUROPE: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 111
TABLE 65 EUROPE: HLA TYPING FOR TRANSPLANTS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 111
TABLE 66 EUROPE: HLA TYPING FOR TRANSPLANTS MARKET, BY END USER, 2021–2028 (USD MILLION) 111
11.3.2 GERMANY 112
11.3.2.1 Germany to dominate European HLA typing for transplants market 112
TABLE 67 GERMANY: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 112
TABLE 68 GERMANY: MOLECULAR ASSAY TECHNOLOGIES MARKET, BY TYPE, 2021–2028 (USD MILLION) 112
TABLE 69 GERMANY: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2021–2028 (USD MILLION) 113
TABLE 70 GERMANY: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2021–2028 (USD MILLION) 113
11.3.3 UK 114
11.3.3.1 Rising number of transplant procedures to drive market 114
TABLE 71 UK: NUMBER OF ORGAN TRANSPLANTATION PROCEDURES, 2019 VS. 2021 114
TABLE 72 UK: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 114
TABLE 73 UK: MOLECULAR ASSAY TECHNOLOGIES MARKET, BY TYPE, 2021–2028 (USD MILLION) 114
TABLE 74 UK: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2021–2028 (USD MILLION) 115
TABLE 75 UK: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2021–2028 (USD MILLION) 115
11.3.4 FRANCE 116
11.3.4.1 Growing adoption of MDx for donor-recipient compatibility testing to support market 116
TABLE 76 FRANCE: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 116
TABLE 77 FRANCE: MOLECULAR ASSAY TECHNOLOGIES MARKET, BY TYPE, 2021–2028 (USD MILLION) 117
TABLE 78 FRANCE: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2021–2028 (USD MILLION) 117
TABLE 79 FRANCE: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2021–2028 (USD MILLION) 117
11.3.5 SPAIN 118
11.3.5.1 Increasing solid organ transplantation procedures to drive market 118
TABLE 80 SPAIN: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 118
TABLE 81 SPAIN: MOLECULAR ASSAY TECHNOLOGIES MARKET, BY TYPE, 2021–2028 (USD MILLION) 118
TABLE 82 SPAIN: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2021–2028 (USD MILLION) 119
TABLE 83 SPAIN: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2021–2028 (USD MILLION) 119
11.3.6 ITALY 119
11.3.6.1 Slowdown in Italian healthcare sector to limit market growth 119
TABLE 84 ITALY: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 120
TABLE 85 ITALY: MOLECULAR ASSAY TECHNOLOGIES MARKET, BY TYPE, 2021–2028 (USD MILLION) 120
TABLE 86 ITALY: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2021–2028 (USD MILLION) 120
TABLE 87 ITALY: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2021–2028 (USD MILLION) 121
11.3.7 REST OF EUROPE 121
TABLE 88 REST OF EUROPE: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 121
TABLE 89 REST OF EUROPE: MOLECULAR ASSAY TECHNOLOGIES MARKET, BY TYPE, 2021–2028 (USD MILLION) 122
TABLE 90 REST OF EUROPE: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2021–2028 (USD MILLION) 122
TABLE 91 REST OF EUROPE: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2021–2028 (USD MILLION) 123
11.4 ASIA PACIFIC 123
11.4.1 ASIA PACIFIC: RECESSION IMPACT 123
FIGURE 27 ASIA PACIFIC: HLA TYPING FOR TRANSPLANTS MARKET SNAPSHOT 124
TABLE 92 ASIA PACIFIC: HLA TYPING FOR TRANSPLANTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 125
TABLE 93 ASIA PACIFIC: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 125
TABLE 94 ASIA PACIFIC: HLA TYPING FOR TRANSPLANTS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 126
TABLE 95 ASIA PACIFIC: HLA TYPING FOR TRANSPLANTS MARKET, BY END USER, 2021–2028 (USD MILLION) 126
11.4.2 CHINA 126
11.4.2.1 Healthcare infrastructural improvements to support market growth 126
TABLE 96 CHINA: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 127
TABLE 97 CHINA: MOLECULAR ASSAY TECHNOLOGIES MARKET, BY TYPE, 2021–2028 (USD MILLION) 127
TABLE 98 CHINA: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2021–2028 (USD MILLION) 127
TABLE 99 CHINA: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2021–2028 (USD MILLION) 128
11.4.3 INDIA 128
11.4.3.1 Increasing transplantation procedures to drive market 128
TABLE 100 INDIA: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 128
TABLE 101 INDIA: MOLECULAR ASSAY TECHNOLOGIES MARKET, BY TYPE, 2021–2028 (USD MILLION) 129
TABLE 102 INDIA: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2021–2028 (USD MILLION) 129
TABLE 103 INDIA: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2021–2028 (USD MILLION) 129
11.4.4 JAPAN 130
11.4.4.1 Significant growth in chronic disease prevalence to support market growth 130
TABLE 104 JAPAN: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 130
TABLE 105 JAPAN: MOLECULAR ASSAY TECHNOLOGIES MARKET, BY TYPE, 2021–2028 (USD MILLION) 130
TABLE 106 JAPAN: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2021–2028 (USD MILLION) 131
TABLE 107 JAPAN: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2021–2028 (USD MILLION) 131
11.4.5 AUSTRALIA 131
11.4.5.1 Rising number of solid organ transplantation procedures to support market growth 131
TABLE 108 AUSTRALIA: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 132
TABLE 109 AUSTRALIA: MOLECULAR ASSAY TECHNOLOGIES MARKET, BY TYPE, 2021–2028 (USD MILLION) 132
TABLE 110 AUSTRALIA: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2021–2028 (USD MILLION) 132
TABLE 111 AUSTRALIA: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2021–2028 (USD MILLION) 133
11.4.6 SOUTH KOREA 133
11.4.6.1 Government support and medical coverage for transplantation to drive market 133
TABLE 112 SOUTH KOREA: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 133
TABLE 113 SOUTH KOREA: MOLECULAR ASSAY TECHNOLOGIES MARKET, BY TYPE, 2021–2028 (USD MILLION) 134
TABLE 114 SOUTH KOREA: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2021–2028 (USD MILLION) 134
TABLE 115 SOUTH KOREA: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2021–2028 (USD MILLION) 134
11.4.7 REST OF ASIA PACIFIC 135
TABLE 116 REST OF ASIA PACIFIC: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 135
TABLE 117 REST OF ASIA PACIFIC: MOLECULAR ASSAY TECHNOLOGIES MARKET, BY TYPE, 2021–2028 (USD MILLION) 135
TABLE 118 REST OF ASIA PACIFIC: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2021–2028 (USD MILLION) 136
TABLE 119 REST OF ASIA PACIFIC: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2021–2028 (USD MILLION) 136
11.5 LATIN AMERICA 136
11.5.1 LATIN AMERICA: RECESSION IMPACT 137
TABLE 120 LATIN AMERICA: HLA TYPING FOR TRANSPLANTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 137
TABLE 121 LATIN AMERICA: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 138
TABLE 122 LATIN AMERICA: HLA TYPING FOR TRANSPLANTS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 138
TABLE 123 LATIN AMERICA HLA TYPING FOR TRANSPLANTS MARKET, BY END USER, 2021–2028 (USD MILLION) 138
11.5.2 BRAZIL 139
11.5.2.1 Brazil to dominate LATAM market 139
TABLE 124 BRAZIL: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 139
TABLE 125 BRAZIL: MOLECULAR ASSAY TECHNOLOGIES MARKET, BY TYPE, 2021–2028 (USD MILLION) 139
TABLE 126 BRAZIL: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2021–2028 (USD MILLION) 140
TABLE 127 BRAZIL: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2021–2028 (USD MILLION) 140
11.5.3 MEXICO 140
11.5.3.1 Rising medical tourism to drive market 140
TABLE 128 MEXICO: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 141
TABLE 129 MEXICO: MOLECULAR ASSAY TECHNOLOGIES MARKET, BY TYPE, 2021–2028 (USD MILLION) 141
TABLE 130 MEXICO: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2021–2028 (USD MILLION) 142
TABLE 131 MEXICO: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2021–2028 (USD MILLION) 142
11.5.4 REST OF LATIN AMERICA 143
TABLE 132 REST OF LATIN AMERICA: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 143
TABLE 133 REST OF LATIN AMERICA: MOLECULAR ASSAY TECHNOLOGIES MARKET, BY TYPE, 2021–2028 (USD MILLION) 143
TABLE 134 REST OF LATIN AMERICA: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2021–2028 (USD MILLION) 144
TABLE 135 REST OF LATIN AMERICA: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2021–2028 (USD MILLION) 144
11.6 MIDDLE EAST & AFRICA 144
11.6.1 GOVERNMENT INITIATIVES AND RISING GERIATRIC POPULATION TO SUPPORT ADOPTION 144
11.6.2 MIDDLE EAST & AFRICA: RECESSION IMPACT 145
TABLE 136 MIDDLE EAST & AFRICA: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 145
TABLE 137 MIDDLE EAST & AFRICA: HLA TYPING FOR TRANSPLANTS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 146
TABLE 138 MIDDLE EAST & AFRICA: HLA TYPING FOR TRANSPLANTS MARKET, BY END USER, 2021–2028 (USD MILLION) 146
12 COMPETITIVE LANDSCAPE 147
12.1 OVERVIEW 147
12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 147
FIGURE 28 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN HLA TYPING FOR TRANSPLANTS MARKET (2020 TO 2023) 148
12.3 REVENUE SHARE ANALYSIS (2022) 149
FIGURE 29 REVENUE ANALYSIS OF TOP FIVE PLAYERS IN HLA TYPING FOR TRANSPLANTS MARKET, 2019–2022 (USD MILLION) 149
12.4 MARKET RANKING SHARE 149
FIGURE 30 HLA TYPING FOR TRANSPLANTS MARKET SHARE, BY KEY PLAYER, 2022 149
TABLE 139 HLA TYPING FOR TRANSPLANTS MARKET: DEGREE OF COMPETITION 150
12.5 COMPANY EVALUATION MATRIX FOR KEY PLAYERS (2022) 151
12.5.1 STARS 151
12.5.2 EMERGING LEADERS 151
12.5.3 PERVASIVE PLAYERS 151
12.5.4 PARTICIPANTS 151
FIGURE 31 HLA TYPING FOR TRANSPLANTS MARKET: COMPANY EVALUATION MATRIX FOR KEY PLAYERS (2022) 152
12.6 COMPANY EVALUATION MATRIX FOR STARTUPS/SMES (2022) 153
12.6.1 PROGRESSIVE COMPANIES 153
12.6.2 STARTING BLOCKS 153
12.6.3 RESPONSIVE COMPANIES 153
12.6.4 DYNAMIC COMPANIES 153
FIGURE 32 HLA TYPING FOR TRANSPLANTS MARKET: COMPANY EVALUATION MATRIX FOR STARTUPS/SMES (AS OF 2022) 154
12.7 COMPETITIVE BENCHMARKING 155
FIGURE 33 COMPANY FOOTPRINT ANALYSIS: TOP FIVE PLAYERS 155
TABLE 140 PRODUCT & SERVICE FOOTPRINT ANALYSIS (TOP FIVE PLAYERS) 155
TABLE 141 REGIONAL FOOTPRINT ANALYSIS (TOP FIVE PLAYERS) 155
TABLE 142 HLA TYPING FOR TRANSPLANTS MARKET: DETAILED LIST OF KEY STARTUPS/SMES 156
12.8 COMPETITIVE SCENARIO 157
12.8.1 PRODUCT LAUNCHES & REGULATORY APPROVALS 157
TABLE 143 KEY PRODUCT LAUNCHES & REGULATORY APPROVALS (2020–2023) 157
12.8.2 DEALS 157
TABLE 144 KEY DEALS (2020–2023) 157
13 COMPANY PROFILES 159
(Business Overview, Products Offered, Recent Developments, MnM View Right to win, Strategic choices made, Weaknesses and competitive threats) *
13.1 KEY PLAYERS 159
13.1.1 THERMO FISHER SCIENTIFIC 159
TABLE 145 THERMO FISHER SCIENTIFIC: COMPANY OVERVIEW 159
FIGURE 34 THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT (2022) 160
13.1.2 ILLUMINA, INC. 164
TABLE 146 ILLUMINA, INC.: COMPANY OVERVIEW 164
FIGURE 35 ILLUMINA, INC.: COMPANY SNAPSHOT (2022) 165
13.1.3 QIAGEN 168
TABLE 147 QIAGEN: COMPANY OVERVIEW 168
FIGURE 36 QIAGEN: COMPANY SNAPSHOT (2022) 169
13.1.4 BIO-RAD LABORATORIES, INC. 172
TABLE 148 BIO-RAD LABORATORIES, INC.: COMPANY OVERVIEW 172
FIGURE 37 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2022) 173
13.1.5 F. HOFFMANN-LA ROCHE LTD. 175
TABLE 149 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW 175
FIGURE 38 F. HOFFMANN-LA ROCHE LTD: COMPANY SNAPSHOT (2022) 176
13.1.6 CAREDX 178
TABLE 150 CAREDX: COMPANY OVERVIEW 178
FIGURE 39 CAREDX: COMPANY SNAPSHOT (2022) 179
13.1.7 IMMUCOR, INC. 182
TABLE 151 IMMUCOR, INC.: COMPANY OVERVIEW 182
13.1.8 LUMINEX CORPORATION (DIASORIN) 184
TABLE 152 DIASORIN S.P.A: COMPANY OVERVIEW 184
FIGURE 40 DIASORIN S.P.A.: COMPANY SNAPSHOT (2022) 185
13.1.9 TBG DIAGNOSTICS LIMITED 186
TABLE 153 TBG DIAGNOSTICS LIMITED: COMPANY OVERVIEW 186
FIGURE 41 TBG DIAGNOSTICS LIMITED: COMPANY SNAPSHOT (2022) 186
13.1.10 FUJIREBIO 188
TABLE 154 FUJIREBIO: COMPANY OVERVIEW 188
13.1.11 OMIXON, INC. 190
TABLE 155 OMIXON, INC.: COMPANY OVERVIEW 190
13.1.12 GENDX 192
TABLE 156 GENDX.: COMPANY OVERVIEW 192
13.1.13 BAG DIAGNOSTICS GMBH 194
TABLE 157 BAG DIAGNOSTICS GMBH: COMPANY OVERVIEW 194
13.1.14 CREATIVE BIOLABS 195
TABLE 158 CREATIVE BIOLABS: COMPANY OVERVIEW 195
13.1.15 PACBIO 196
TABLE 159 PACBIO: COMPANY OVERVIEW 196
FIGURE 42 PACBIO: COMPANY SNAPSHOT (2022) 197
13.2 OTHER PLAYERS 199
13.2.1 HISTOGENETICS LLC 199
13.2.2 SCISCO GENETICS, INC. 199
13.2.3 INNO-TRAIN DIAGNOSTIK GMBH 200
13.2.4 BIONOBIS 200
13.2.5 QUEST DIAGNOSTICS 201
13.2.6 SCIENCELL RESEARCH LABORATORIES, INC. 202
13.2.7 BGI GENOMICS 203
13.2.8 CEGAT GMBH 203
13.2.9 PROIMMUNE LTD. 204
13.2.10 CD GENOMICS 204
*Details on Business Overview, Products Offered, Recent Developments, MnM View, Right to win, Strategic choices made, Weaknesses and competitive threats might not be captured in case of unlisted companies.
14 APPENDIX 205
14.1 DISCUSSION GUIDE 205
14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 209
14.3 CUSTOMIZATION OPTIONS 211
14.4 RELATED REPORTS 211
14.5 AUTHOR DETAILS 212